In this envelope, 935 million will be disbursed between 2022 and 2026, said Jean Castex, welcoming “the ambition to develop six candidate messenger RNA vaccines by 2025”, targeted on infectious and emerging diseases.
Article written by
Posted
Update
Reading time : 1 min.
The French laboratory Sanofi will invest 1.5 billion euros in France to develop the innovative technology of messenger RNA, Jean Castex announced on Monday March 7 from the group’s site in Neuville-sur-Saône (Rhône).
In this envelope, 935 million will be disbursed between 2022 and 2026, specified the Prime Minister, welcoming “the ambition to develop six candidate messenger RNA vaccines by 2025”targeting infectious and emerging diseases.
Recalling the “national trauma that this race for vaccines has been” against Covid-19, in which Sanofi was largely relegated by its competitors (Pfizer, Moderna, etc.), Jean Castex laid the foundation stone for a new production unit in Neuville-sur-Saône, the construction of which had was announced by Emmanuel Macron in June 2020.
“We wanted to have a reflection on European sovereignty. It is important to be able to have on French and European soil production capacities from A to Z on messenger RNA”said Olivier Bogillot, the group’s president in France.